Alector, Inc. (ALEC) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
ALEC currently has 111M outstanding shares. with limited dilution risk as only 14.1M additional shares (12.7%) are authorized for issuance. The company has diluted shareholders by 14.77% over the past 2 years through share issuances.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 07, 2026 |
10-Q filing | 110.6M shares outstanding |
110M | 14M |
| Mar 12, 2026 |
S-3 filing: Alector, Inc. may offer and sell common stock, preferred stock, debt securities, warrants, purchase contracts, and units from time to time in one or more offerings, up to a total amount of $400,000,000. |
100M | 14M |
| Nov 06, 2025 |
10-Q filing | 102.6M shares outstanding |
100M | 14M |
| Aug 07, 2025 |
10-Q filing | 100.4M shares outstanding |
100M | 14M |
| May 08, 2025 |
10-Q filing | 99.4M shares outstanding |
99M | 14M |
| Feb 26, 2025 |
10-K filing | 96.6M shares outstanding |
97M | 14M |
| Nov 06, 2024 |
10-Q filing | 97.5M shares outstanding |
98M | 14M |
| Aug 07, 2024 |
10-Q filing | 96.7M shares outstanding |
97M | 14M |
| May 08, 2024 |
10-Q filing | 93.8M shares outstanding |
94M | 14M |
| Feb 27, 2024 |
10-K filing | 95.7M shares outstanding |
96M | 14M |
| Nov 07, 2023 |
10-Q filing | 83.9M shares outstanding |
84M | 14M |
| Aug 03, 2023 |
10-Q filing | 83.6M shares outstanding |
84M | 14M |
| May 04, 2023 |
10-Q filing | 83.1M shares outstanding |
83M | 14M |
| Feb 28, 2023 |
S-3 filing: Alector, Inc. files an S-3 to offer and sell common stock, preferred stock, and debt securities for up to $400,000,000 from time to time in one or more offerings. |
83M | 14M |
| Feb 28, 2023 |
10-K filing | 82.5M shares outstanding |
82M | 14M |
| Nov 08, 2022 |
10-Q filing | 82.6M shares outstanding |
83M | 14M |
| Aug 04, 2022 |
10-Q filing | 82.6M shares outstanding |
83M | 14M |
| May 05, 2022 |
10-Q filing | 82.3M shares outstanding |
82M | 14M |
| Feb 24, 2022 |
10-K filing | 82.0M shares outstanding |
82M | 14M |
| Nov 04, 2021 |
10-Q filing | 81.0M shares outstanding |
81M | 14M |
| Aug 03, 2021 |
10-Q filing | 80.9M shares outstanding |
81M | 14M |
| May 05, 2021 |
10-Q filing | 79.8M shares outstanding |
80M | 14M |
| Feb 25, 2021 |
10-K filing | 79.6M shares outstanding |
80M | 14M |
| Nov 10, 2020 |
10-Q filing | 79.2M shares outstanding |
79M | 14M |
| Aug 11, 2020 |
10-Q filing | 79.3M shares outstanding |
79M | 14M |
| May 13, 2020 |
10-Q filing | 79.0M shares outstanding |
79M | 14M |
| Mar 24, 2020 |
10-K filing | 79.0M shares outstanding |
79M | 14M |
| Jan 29, 2020 |
S-1/A filing: This S-1/A filing includes information about a common stock offering, with 7,000,000 shares offered by the company and an additional 1,050,000 shares available through the underwriters' option. The net proceeds are estimated to be approximately $160.8 million, or $185.1 million if the underwriters exercise their option in full, and will be used for clinical trials, pipeline advancement, and general corporate activities. |
69M | 14M |
| Jan 27, 2020 |
S-1 filing: The filing is an S-1 registration statement for a proposed offering of common stock. The company intends to use the net proceeds from this offering to fund clinical trials, advance its preclinical development pipeline, further develop its Discovery Platform, and to fund working capital and other general corporate activities. |
69M | 11M |